Comments
Strides Pharma Global, the wholly-owned subsidiary of Strides Shasun, has received approval for Nystatin and Triamcinolone Acetonide ointment and Piroxicam capsules, used to treat fungal skin infections.
Strides got the nod from the US Food and Drug Administration (FDA) a few days after receiving an approval to market the Hepatitis and HIV drug in the US.
This product is an important new addition to Strides’ portfolio of oral solid dosage products and the Bengaluru manufacturing plant supports several current and future topical submissions for the US market, the company said.
The product will be marketed by Strides Pharma Inc. in the US market.
The US market for Piroxicam is approximately $11 million and for Nystatin and Triamcinolone Acetonide ointment USP, 0.1 per cent is about $18 million, according to the IMS sales data.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.